CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21,471 enrolled
Drug / intervention
Telmisartandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00659581
NCT00659581N/ACompleted

Special Survey (Survey on Cerebrovascular and Cardiovascular Events Under Long-term Use) of Micardis Tablets (Telmisartan)

Boehringer Ingelheim·observational·Posted Apr 16, 2008·Updated Aug 25, 2016

In Brief

An observational study evaluating Telmisartan for Hypertension. Completed, enrolled 21,471 participants.

Detailed Summary

The primary objective of this post marketing survey is to prospectively investigate patients with hypertension treated with Micardis Tablets (hereinafter "this drug") in routine clinical settings for 3 years in order to determine the following: 1. Adverse events and adverse drug reactions under long-term use 2. Blood pressure measurements during the survey period 3. Determination of the incidence of cerebrovascular and cardiovascular events under use of this drug in routine clinical settings 4. Patient's lifestyle and background factors that are considered to affect the occurrence of cerebrovascular and cardiovascular events

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 16, 2008
Enrollment StartApr 1, 2006
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 18.2 years ago

Interventions

Telmisartandrug

Oral administration